Treatment Satisfaction and Its Associated Factors of Dolutegravir Based Regimen in a Resource Limited Setting

References

• Langerman H, Gadsby R. Treatment satisfaction: a neglected but important outcome measure in older people with type 2 diabetes. J Ageing Res Clin Pract. 2017;6:124–132.
   Google Scholar
• Sweileh WM, Ihbesheh MS, Jarar IS, et al. Self-reported medication adherence and treatment satisfaction in patients with epilepsy. Epilep Behav. 2011;21(3):301–305. doi:10.1016/j.yebeh.2011.04.011
   Web of Science ®Google Scholar
• Mayberry RM, Nicewander DA, Qin H, Ballard DJ. Improving quality and reducing inequities: a challenge in achieving best care. World Hosp Health Serv. 2008;44(3):16–31.
   Google Scholar
• World Health Organization. Update of Recommendations on First‐and Second‐line Antiretroviral Regimens. World Health Organization; 2019.
   Google Scholar
• Ryom L, Cotter A, De Miguel R, et al. 2019 update of the European AIDS clinical society guidelines for treatment of people living with HIV version 10.0. HIV Med. 2020;21(10):617–624. doi:10.1111/hiv.12878
   PubMed Web of Science ®Google Scholar
• Walmsley S, Baumgarten A, Berenguer J, et al. Brief report: dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. JAIDS. 2015;70(5):515. doi:10.1097/QAI.0000000000000790
   Web of Science ®Google Scholar
• Group NAS. Dolutegravir-based or low-dose Efavirenz–based regimen for the treatment of HIV-1. N Engl J Med. 2019;381(9):816–826. doi:10.1056/NEJMoa1904340
   Web of Science ®Google Scholar
• Weldring T, Smith SM. Article commentary: patient-reported outcomes (pros) and patient-reported outcome measures (PROMs). Health Serv Insights. 2013;6:S11093. doi:10.4137/HSI.S11093
   Google Scholar
• Walters-Salas E. The challenge of patient adherence. Bariatric Nur Surg Patient Care. 2012;7(4):186. doi:10.1089/bar.2012.9960
   Web of Science ®Google Scholar
• Mosadeghrad AM. Factors affecting medical service quality. Iran J Public Health. 2014;43(2):210.
   PubMed Web of Science ®Google Scholar
• Vo BN, Cohen CR, Smith RM, et al. Patient satisfaction with integrated HIV and antenatal care services in rural Kenya. AIDS Care. 2012;24(11):1442–1447. doi:10.1080/09540121.2011.652357
   PubMed Web of Science ®Google Scholar
• Njilele A, Ukwe C, Okonta J, Ekwunife O. Development of a patient satisfaction questionnaire for HIV/AIDS patients in Nigeria. Int J Clin Pharm. 2012;34(1):98–104. doi:10.1007/s11096-011-9596-9
   Web of Science ®Google Scholar
• Devnani M, Gupta AK, Wanchu A, Sharma RK. Factors associated with health service satisfaction among people living with HIV/AIDS: a cross sectional study at ART center in Chandigarh, India. AIDS Care. 2012;24(1):100–107. doi:10.1080/09540121.2011.592816
   PubMed Web of Science ®Google Scholar
• Willke RJ. Measuring the value of treatment to patients: patient-reported outcomes in drug development. Am Health Drug Benefits. 2008;1(1):34.
   PubMedGoogle Scholar
• Balfour L, Kowal J, Tasca G, et al. Development and psychometric validation of the HIV treatment knowledge scale. AIDS Care. 2007;19(9):1141–1148. doi:10.1080/09540120701352241
   PubMed Web of Science ®Google Scholar
• Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47(6):555–567. doi:10.1016/S0022-3999(99)00057-4
   PubMed Web of Science ®Google Scholar
• Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical Construct Validity of the Treatment Satisfaction Questionnaire for Medication (TSQM Version II) Among Outpatient Pharmacy Consumers. Elsevier; 2005.
   Google Scholar
• Zajacova A, Dowd JB. Reliability of self-rated health in US adults. Am J Epidemiol. 2011;174(8):977–983. doi:10.1093/aje/kwr204
   PubMed Web of Science ®Google Scholar
• O’brien RM. A caution regarding rules of thumb for variance inflation factors. Qual Quant. 2007;41(5):673–690. doi:10.1007/s11135-006-9018-6
   Web of Science ®Google Scholar
• Hosmer DW, Lemeshow S, Sturdivant RX. Applied Logistic Regression. John Wiley & Sons; 2013.
   Google Scholar
• Evaluation FD. Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment. Guidance for industry. 2015.
   Google Scholar
• Oglesby A, Punekar A, Angelis K, et al. Patient reported outcomes after switching to a 2 drug regimen of dolutegravir+ rilpivirine: results from the SWORD-1 and SWORD-2 studies. 16th European AIDS conference; 2017.
   Google Scholar
• Trottier B, Lake JE, Logue K, et al. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, phase IIIb study. Antivir Ther. 2017;22(4):295–305. doi:10.3851/IMP3166
   PubMed Web of Science ®Google Scholar
• Mondi A, Cozzi‐Lepri A, Tavelli A, et al. Effectiveness of dolutegravir‐based regimens as either first‐line or switch antiretroviral therapy: data from the Icona cohort. J Int AIDS Soc. 2019;22(1):e25227. doi:10.1002/jia2.25227
   PubMed Web of Science ®Google Scholar
• Del Mar Gutierrez M, Mateo MG, Vidal F, Domingo P. Drug safety profile of integrase strand transfer inhibitors. Expert Opin Drug Saf. 2014;13(4):431–445. doi:10.1517/14740338.2014.897327
   PubMed Web of Science ®Google Scholar
• Dolutegravir W. And the Fixed Dose Combination (FDC) of Tenofovir/Lamivudine/dolutegravir (TLD). Geneva: World Health Organisation; 2018.
   Google Scholar
• Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19(2):124. doi:10.1037/0278-6133.19.2.124
   PubMed Web of Science ®Google Scholar
• Katz IT, Ryu AE, Onuegbu AG, et al. Impact of HIV‐related stigma on treatment adherence: systematic review and meta‐synthesis. J Int AIDS Soc. 2013;16:18640. doi:10.7448/IAS.16.3.18640
   PubMed Web of Science ®Google Scholar
• Ingersoll KS, Heckman CJ. Patient–clinician relationships and treatment system effects on HIV medication adherence. AIDS Behav. 2005;9(1):89–101. doi:10.1007/s10461-005-1684-1
   PubMed Web of Science ®Google Scholar
• Flickinger TE, Saha S, Moore RD, Beach MC. Higher quality communication and relationships are associated with improved patient engagement in HIV care. JAIDS. 2013;63(3):362. doi:10.1097/QAI.0b013e318295b86a
   Web of Science ®Google Scholar
• Kalichman SC, Pope H, White D, et al. Association between health literacy and HIV treatment adherence: further evidence from objectively measured medication adherence. J Int Assoc Physicians AIDS Care. 2008;7(6):317–323. doi:10.1177/1545109708328130
   Google Scholar
• Kremer H, Ironson G, Porr M. Spiritual and mind–body beliefs as barriers and motivators to HIV-treatment decision-making and medication adherence? A qualitative study. AIDS Patient Care STDS. 2009;23(2):127–134. doi:10.1089/apc.2008.0131
   PubMed Web of Science ®Google Scholar
• Adefolalu A, Nkosi Z, Olorunju S, Masemola P. Self-efficacy, medication beliefs and adherence to antiretroviral therapy by patients attending a health facility in Pretoria. South Afr Fam Pract. 2014;56(5):281–285. doi:10.1080/20786190.2014.975476
   Google Scholar
• Langebeek N, Gisolf EH, Reiss P, et al. Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis. BMC Med. 2014;12(1):1–14.
   Web of Science ®Google Scholar
• Godin G, Cote J, Naccache H, Lambert L-D, Trottier S. Prediction of adherence to antiretroviral therapy: a one-year longitudinal study. AIDS Care. 2005;17(4):493–504. doi:10.1080/09540120412331291715
   PubMed Web of Science ®Google Scholar
• Grierson J, Koelmeyer R, Smith A, Pitts M. Adherence to antiretroviral therapy: factors independently associated with reported difficulty taking antiretroviral therapy in a national sample of HIV‐positive Australians. HIV Med. 2011;12(9):562–569. doi:10.1111/j.1468-1293.2011.00928.x
   PubMed Web of Science ®Google Scholar
• Kerr T, Palepu A, Barness G, et al. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver. Antiviral Ther. 2004;9(3):407–414.
   Web of Science ®Google Scholar
• Boateng D, Kwapong GD, Agyei-Baffour P. Knowledge, perception about antiretroviral therapy (ART) and prevention of mother-to-child-transmission (PMTCT) and adherence to ART among HIV positive women in the Ashanti Region, Ghana: a cross-sectional study. BMC Womens Health. 2013;13(1):1–8. doi:10.1186/1472-6874-13-2
   Web of Science ®Google Scholar
• Gourlay A, Birdthistle I, Mburu G, Iorpenda K, Wringe A. Barriers and facilitating factors to the uptake of antiretroviral drugs for prevention of mother‐to‐child transmission of HIV in sub‐Saharan Africa: a systematic review. J Int AIDS Soc. 2013;16(1):18588. doi:10.7448/IAS.16.1.18588
   PubMed Web of Science ®Google Scholar
• Lifson AR, Demissie W, Tadesse A, et al. Barriers to retention in care as perceived by persons living with HIV in rural Ethiopia: focus group results and recommended strategies. JIAPAC. 2013;12(1):32–38. doi:10.1177/1545109712456428
   Google Scholar
• Kuritzkes DR. Preventing and managing antiretroviral drug resistance. AIDS Patient Care STDs. 2004;18(5):259–273. doi:10.1089/108729104323076007
   PubMed Web of Science ®Google Scholar
• Press N, Tyndall MW, Wood E, Hogg RS, Montaner J. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. JAIDS. 2002;31:S112–7. doi:10.1097/00126334-200212153-00005
   Web of Science ®Google Scholar
• Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. Aids. 2000;14(4):357–366. doi:10.1097/00002030-200003100-00008
   PubMed Web of Science ®Google Scholar
• Little SJ, Holte S, Routy J-P, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347(6):385–394. doi:10.1056/NEJMoa013552
   PubMed Web of Science ®Google Scholar
• Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30. doi:10.7326/0003-4819-133-1-200007040-00004
   PubMed Web of Science ®Google Scholar
• Burch LS, Smith CJ, Anderson J, et al. Socioeconomic status and treatment outcomes for individuals with HIV on antiretroviral treatment in the UK: cross-sectional and longitudinal analyses. Lancet Public Health. 2016;1(1):e26–e36. doi:10.1016/S2468-2667(16)30002-0
   PubMed Web of Science ®Google Scholar
• Kalichman SC, Washington C, Grebler T, et al. Medication adherence and health outcomes of people living with HIV who are food insecure and prescribed antiretrovirals that should be taken with food. Infect Dis Ther. 2015;4(1):79–91. doi:10.1007/s40121-015-0057-y
   Web of Science ®Google Scholar
• Moralejo L, Inés S, Marcos M, Fuertes A, Luna G. Factors influencing adherence to highly active antiretroviral therapy in Spain. Curr HIV Res. 2006;4(2):221–227. doi:10.2174/157016206776055075
   PubMed Web of Science ®Google Scholar
• Goldman DP, Smith JP. Can patient self-management help explain the SES health gradient? Proc Natl Acad Sci. 2002;99(16):10929–10934. doi:10.1073/pnas.162086599
   PubMed Web of Science ®Google Scholar
• Weiser SD, Frongillo EA, Ragland K, Hogg RS, Riley ED, Bangsberg DR. Food insecurity is associated with incomplete HIV RNA suppression among homeless and marginally housed HIV-infected individuals in San Francisco. J Gen Intern Med. 2009;24(1):14–20. doi:10.1007/s11606-008-0824-5
   PubMed Web of Science ®Google Scholar
• Marzolini C, Back D, Weber R, et al. Ageing with HIV: medication use and risk for potential drug–drug interactions. J Antimicrob Chemother. 2011;66(9):2107–2111. doi:10.1093/jac/dkr248
   PubMed Web of Science ®Google Scholar
• Cantudo-Cuenca MR, Jiménez-Galán R, Almeida-González CV, Morillo-Verdugo R. Concurrent use of comedications reduces adherence to antiretroviral therapy among HIV-infected patients. J Manag Care Pharm. 2014;20(8):844–850. doi:10.18553/jmcp.2014.20.8.844
   Google Scholar
• García de Olalla P, Knobel H, Carmona A, Guelar A, López-Colomés JL, Caylà JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. AIDS. 2002;30(1):105–110.
   Google Scholar
• Lima VD, Harrigan R, Bangsberg DR, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. JAIDS. 2009;50(5):529. doi:10.1097/QAI.0b013e31819675e9
   Web of Science ®Google Scholar
• Nieuwkerk PT, Oort FJ. Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis. JAIDS. 2005;38(4):445–448. doi:10.1097/01.qai.0000147522.34369.12
   Web of Science ®Google Scholar